COPD: Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Expression and Predictive Value of Angiopoietin-2 in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.","authors":"Ruiqin Ni, Mengrong Xie, Jingying Zhang, Mingmei Zhong","doi":"10.1080/15412555.2025.2512749","DOIUrl":"https://doi.org/10.1080/15412555.2025.2512749","url":null,"abstract":"<p><p>Clear and effective treatment for pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD) has not been established, and thus promptly identifying patients with PH is of particular importance. In this study, by comparing Angiopoietin-2 expression in patients with COPD and COPD-PH, we analysed the risk factors of PH and evaluated the predictive value of these in PH. Therefore, this prospective study selected COPD of patients as research subjects, which were divided into COPD and COPD-PH groups according to whether they were complicated with PH. Lung function, general laboratory index, N-terminal pro brain b-type natriuretic peptide (NT-proBNP), Angiopoietin-2, and other cytokines levels were compared between the two groups, and the risk factors of COPD-PH were explored through multivariate binary regression analysis. Lastly, receiver operating characteristic curve was used in evaluating the predictive value of risk factors for COPD-PH. The results show that the COPD-PH group has higher Angiopoietin-2, logistic analysis showed that Angiopoietin-2, NT-proBNP, age, and FEV1%pred were independent risk factors for COPD-PH and had high predictive value for COPD-PH. The AUROC for Angiopoietin-2 and NT-proBNP for predicting COPD-PH were 0.646 and 0.751. When Angiopoietin-2 ≥ 39.55 pg/ml, NT-proBNP ≥ 134.03 pg/ml, the sensitivity for COPD-PH prediction was 44.7 and 93.6%, respectively, and the specificity rates were 83.1 and 49.2%, respectively. When Angiopoietin-2 was combined with NT-proBNP, enhanced the AUROC to 0.766, exceeding Angiopoietin-2 alone, which may be useful in the prediction of COPD-PH.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2512749"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Experience of Automated Home Oxygen Therapy for Patients With COPD - A Qualitative Study.","authors":"Linette Marie Kofod, Louise Bolvig Laursen, Elisabeth Westerdahl, Ejvind Frausing Hansen, Barbara Cristina Brocki, Morten Tange Kristensen, Dorthe Gaby Bove","doi":"10.1080/15412555.2025.2477243","DOIUrl":"10.1080/15412555.2025.2477243","url":null,"abstract":"<p><p>The present study included the first patients with COPD on long-term oxygen therapy who experienced second-by-second oxygen adjustments in their homes based on oxygen saturation. A device capable of automatically titrating the patient's oxygen was installed in the patients' home aiming at increasing the time spent within target saturation. We explored patients' experiences with this automated home oxygen titration, focusing on how maintaining target saturation affected daily life. Semi-structured interviews were conducted with eight men and four women after installation. Systematic text condensation was used in the analysis. Three main themes emerged from patient narratives: (1) \"This is my life\" - Patients preferred maintaining stable oxygen saturation, associating hypoxemia with dyspnea, discomfort, and difficulties with daily tasks. (2) \"Getting the oxygen, I need\" - Many patients reported improved ability to perform daily activities when oxygen was automatically adjusted. (3) \"New technology gives hope for my life\" - Patients expressed optimism about the potential of home-based technology, offering suggestions to improve usability, mainly by reducing concentrator noise. Our findings suggested high acceptability of the automated oxygen in the patients' home, as they believed it to increase the time spend with sufficient oxygen, especially during daily activities. Integrating patient insights is essential for implementation and acceptance of automated home oxygen therapy.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2477243"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of ABCA1 in Chronic Obstructive Pulmonary Disease.","authors":"Ying Gu, Xiaoqing Bi, Xiaofei Liu, Qingqing Qian, Yiqiong Wen, Shu Hua, Qiaoli Fu, Yuanyuan Zheng, Shibo Sun","doi":"10.1080/15412555.2025.2493701","DOIUrl":"https://doi.org/10.1080/15412555.2025.2493701","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is one of the common chronic respiratory diseases, which causes a heavy burden to patients and society. Increasing studies suggest that ABCA1 plays an important role in COPD. ABCA1 belongs to a large class of ATP-binding (ABC) transporters. It is not only involved in the reverse transport of cholesterol, but also in the regulation of apoptosis, pyroptosis, cellular inflammation and cellular immunity. Meanwhile, ABCA1 is involved in several signaling pathways, such as SREBP pathway, LXR pathway, MAPK pathway, p62/mTOR pathway, CTRP1 pathway and so on. In addition, the ABCA1 participates in the disorder of lipid metabolism in COPD by regulating the formation of RCT and HDL, regulates the inflammation of COPD by removing excess cholesterol in macrophages, and promotes the differentiation of COPD phenotype into emphysema type. Accordingly, the ABCA1 may be a therapeutic target for COPD.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2493701"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics in COPD: The Road is Still Long and Winding.","authors":"Konstantinos Kostikas, Athena Gogali","doi":"10.1080/15412555.2025.2467657","DOIUrl":"https://doi.org/10.1080/15412555.2025.2467657","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2467657"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Association of Lipid-Lowering Drug Target Genes with Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study.","authors":"Hao Luan, Tianhua Wang, Rui Wang, Yu Wang, Yu Liu, Wenru Sheng, Jiaqi Guo, Haotian Ji, Xiufeng Liu, Xiqing Xue, Yiider Tseng","doi":"10.1080/15412555.2025.2513601","DOIUrl":"https://doi.org/10.1080/15412555.2025.2513601","url":null,"abstract":"<p><p>The role of lipid-lowering drugs in chronic obstructive pulmonary disease (COPD) is controversial in clinical studies. This study aimed to explore the causal relationship between lipid-lowering drugs and COPD from a genetic perspective, and to evaluate the potential effects of this relationship. Four hundred and thirty-one lipid-related phenotypes and two COPD datasets were obtained from Genome-Wide Association Studies (GWAS) and analysed together using Mendelian randomization (MR). Genetic variants associated with genes encoding targets of lipid-lowering drugs were extracted from the Global Lipid Genetics Consortium. Expression quantitative trait loci data in relevant tissues were adopted to validate lipid-lowering drug targets that reached significance. We found that four lipid abnormalities were associated with COPD risk. Genetically proxied inhibition of HMG-CoA reductase (HMGCR) and PCSK9 is associated with an increased risk of COPD. And there is a significant MR correlation between increased whole blood HMGCR expression and COPD. HMGCR and PCSK9 inhibitors are associated with onset of COPD, lung function, and COPD-associated infections. Mediation analyses were performed to explore potential mediators of how genetically proxied inhibition of HMGCR and PCSK9 influences the risk of COPD through different immune cell phenotypes and inflammatory factor levels. Our findings indicate a potential link between the use of HMGCR and PCSK9 inhibitors and increased risk of COPD and exacerbation of COPD phenotypes. This suggests effects beyond LDL-C modulation, potentially involving immune cell function and inflammatory factors.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2513601"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use, Effectiveness, and Safety of Inhaler Devices for LABA/LAMA Fixed-Dose Combinations in Patients with COPD.","authors":"Sara Lopes, Maria Lucia Marino, Filomena Fortinguerra, Nera Agabiti, Valeria Belleudi, Francesco Trotta","doi":"10.1080/15412555.2025.2506548","DOIUrl":"10.1080/15412555.2025.2506548","url":null,"abstract":"<p><p>In Italy, long-acting bronchodilator (LABA/LAMA) fixed-dose combinations are widely used for treating chronic obstructive pulmonary disease (COPD). These medications are available in various inhaler devices, but clinical guidelines do not recommend a specific device, leaving the choice to clinicians based on patient needs. To date, no studies have directly compared the effectiveness and safety of different LABA/LAMA devices. This retrospective observational study evaluated the utilization, effectiveness, and safety of LABA/LAMA inhaler devices in COPD patients in the Lazio region, representing about 10% of Italy's population. Patients aged 45 and older who initiated LABA/LAMA treatment between January 2017 and December 2019 were included. The devices analyzed were dry powder inhalers (DPI) capsule/strip (DPI-<i>t</i>, reference group), DPI with a reservoir (DPI-r), and soft mist inhalers (SMI). The study identified 12,346 eligible patients, with over 80% having prior COPD drug use. Of these, 53.2% used DPI-<i>t</i>, 19.7% DPI-r, and 27.1% SMI. No significant differences in severe exacerbations, mortality, pneumonia, or cerebro-cardiovascular events were observed among the devices. Hazard ratios for key outcomes (e.g., severe exacerbations, mortality) showed overlapping confidence intervals across device types, suggesting no device offered superior effectiveness or safety. This is the first study to assess LABA/LAMA device use in real-world clinical practice for COPD. Findings suggest therapeutic equivalence among devices, supporting flexibility in prescribing. Further research is needed to inform cost-effective prescribing policies for LABA/LAMA therapies.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2506548"},"PeriodicalIF":2.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis Should Not Be Simply Conducted By Default: Biologic Therapy for Chronic Obstructive Pulmonary Disease.","authors":"Jean Bourbeau, Claudia LeBlanc, Bryan Ross, Darcy Marciniuk","doi":"10.1080/15412555.2025.2501548","DOIUrl":"https://doi.org/10.1080/15412555.2025.2501548","url":null,"abstract":"","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2501548"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Passive Cough Monitoring Predict COPD Exacerbations?","authors":"A H Morice, A C den Brinker, M Crooks, S Thackray-Nocera, O Ouweltjes, R Rietman","doi":"10.1080/15412555.2025.2487909","DOIUrl":"https://doi.org/10.1080/15412555.2025.2487909","url":null,"abstract":"<p><strong>Purpose: </strong>Validation of an alert mechanism for COPD exacerbations based on coughing detected by a stationary unobtrusive nighttime monitor.</p><p><strong>Methods: </strong>This prospective double-blind longitudinal study of cough monitoring included 40 chronic obstructive pulmonary disease (COPD) patients. Participants underwent cough monitoring and completed a daily questionnaire for 12 weeks. If no exacerbation occurred within that period patients were asked to continue being monitored for a further 12 weeks. The automated system identified deteriorating trends in cough based on a personalized cough classifier and the alerts were compared with patient reported exacerbation onsets.</p><p><strong>Results: </strong>Thirty-eight patients [median age 72 (range 57-84)], median FEV-1% predicted 43% (range 20-106%) completed the study and had 41 exacerbations over a total of 3981 days. For 32 patients, the cough monitor data allowed classifier personalization, trend analysis, and alert generation. Based on the trend data, it is estimated that ∼30% of exacerbations are not associated with an increase in cough. The alert mechanism flagged 59% of the exacerbations. For the cases with alerts preceding the onset, the associated lead time was 4 days or more.</p><p><strong>Conclusion: </strong>Though based on a single variable only, the cough-based alert system captured more than half of the exacerbations in a passive, free-living scenario. No adherence issues were reported, and patients confirmed the unobtrusive and hassle-free nature of the approach.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2487909"},"PeriodicalIF":2.2,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home-Based Inspiratory Muscle Training as Stand-Alone Therapy in COPD: A Randomized Sham-Controlled Trial Assessing Novel and Established Training Methods.","authors":"Martin Hartman, Filip Dosbaba, Ladislav Batalik, Daniela Vlazna, Marek Plutinsky, Kristian Brat, Roberta Catunda Costa, Artur Solon Lima, Lawrence P Cahalin, Magno F Formiga","doi":"10.1080/15412555.2025.2487473","DOIUrl":"10.1080/15412555.2025.2487473","url":null,"abstract":"<p><p>This randomized controlled trial evaluated the effectiveness of two home-based, stand-alone inspiratory muscle training (IMT) modalities - inspiratory flow-resistive loading with biofeedback (IRFL) and mechanical threshold loading (MTL) - compared to a sham MTL group for improving inspiratory muscle performance and functional exercise capacity in COPD patients. Thirty-six COPD patients trained at home for 8 weeks under remote monitoring. Primary outcomes included inspiratory muscle performance assessed <i>via</i> the Test of Incremental Respiratory Endurance (TIRE), functional exercise capacity, lung function, and other COPD-related measures. Both the TIRE IRFL and MTL groups showed significant improvements in inspiratory muscle strength compared to the sham MTL group (<i>p</i> < 0.05). Additionally, the IRFL with biofeedback group demonstrated significant gains in inspiratory muscle work capacity and 6MWT distance compared to both the MTL and sham groups (<i>p</i> < 0.05). No adverse events were reported, and adherence to training protocols was high across all groups. This study supports home-based IMT as a feasible, effective stand-alone intervention for COPD patients, particularly for those who face barriers in accessing traditional pulmonary rehabilitation programs. TIRE IFRL showed superior benefits in enhancing inspiratory muscle function and overall functional exercise capacity compared to fixed-load IMT.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2487473"},"PeriodicalIF":2.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations in Adiponectin Expression in Models of Cigarette Smoke Extract-Induced Mouse Pulmonary Emphysema and Alveolar Epithelial Cell Injury.","authors":"Siriporn Vongsaiyat Siriphorn, Supitsara Thorsuwan, Julalux Thongam, Sukpattaraporn Ruangklai, Poungpetch Hussarin, Thanaporn Rungruang, Sorachai Srisuma","doi":"10.1080/15412555.2025.2477235","DOIUrl":"10.1080/15412555.2025.2477235","url":null,"abstract":"<p><strong>Purpose: </strong>Cigarette smoke activates lung inflammation and destruction and the development of COPD. Among various factors influenced by lung inflammation, adiponectin produced by lung epithelial cells is thought to play a significant role in regulating inflammation and maintaining tissue integrity. This study aims to examine adiponectin expression in a mouse model of cigarette smoke extract (CSE)-induced emphysema and explore the effects of adiponectin on cell survival and cytokine gene expression in CSE-induced lung epithelial cell damage.</p><p><strong>Methods: </strong>CSE was prepared by passing cigarette smoke through a glass tube containing solvent. PBS or CSE was intraperitoneally administered to C57BL/6 mice. Inflammatory cells, cytokines, adiponectin expression in lung, bronchoalveolar lavage fluid (BALF) and adipose tissue were assessed. CSE and adiponectin were administered to A549 cells to determine cell viability and cytokine gene expression.</p><p><strong>Results: </strong>Intraperitoneal CSE injection significantly increased the mean alveolar linear intercept by 23.11%. CSE significantly increased total cells, macrophages, neutrophils, eosinophils, TNFα, IL-1β levels in BALF. CSE enhanced lung adiponectin protein expression. Treatment of A549 cells with CSE reduced cell survival and adiponectin gene expression. Furthermore, adiponectin treatment enhanced MCP-1 and IL-8 gene expression in A549 cells post-CSE exposure.</p><p><strong>Conclusion: </strong>Intraperitoneal CSE treatment induced lung inflammation, airspace enlargement, and increased adiponectin expression in mice. CSE-exposed A549 cells showed reduced cell viability, upregulated proinflammatory genes, downregulated adiponectin genes. Adiponectin treatment further intensified these genes expressions, aligning with <i>in vivo</i> findings. Elevated adiponectin expression in alveolar epithelial cells suggests its potential role in the development of COPD by enhancing lung inflammation.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2477235"},"PeriodicalIF":2.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}